CombiMatrix (CBMX) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Alaska LNG shipping savings justifies billions in investment, developer says
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
CombiMatrix Corporation Reports Second Quarter 2015 Financial and Operating Results
August 5, 2015 4:06 PM EDTMarks 7th Consecutive Quarter of Record Prenatal Microarray Test Revenues and Volumes
Conference Call Begins Today at 4:30 p.m. Eastern Time
IRVINE, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ: CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, today reported financial results for the quarter and six months ended June 30, 2015, and provided a business update.
"Our business momentum remains strong as evidenced by another quarter of record revenues and volume from our prenatal... More



